When does Viberzi lose exclusivity and become generic?
Viberzi (eluxadoline) is marketed as a brand drug in the U.S., but the exact date when a generic version can launch depends on patent and regulatory exclusivity status in the U.S. (and on the timing of approved generic filings). The information provided here does not include Viberzi’s patent expiration dates or FDA exclusivity/approval history, so a specific “generic start” date cannot be determined from the given materials.
What usually controls the generic timing for a drug like Viberzi?
Generic availability is typically driven by:
- Patent expiration (and whether any patents are still listed for the drug).
- FDA regulatory exclusivity (for example, exclusivity that can delay approval of certain applications even after some patents expire).
- When an ANDA applicant can receive approval to market the generic (which may be later than the first patent expiration date due to other continuing protections).
How can you find the exact generic-launch date for Viberzi?
To get the most accurate U.S. timing, check:
- FDA’s Orange Book for Viberzi to see the listed patents and their expiration dates.
- Any court activity or patent “carve-outs” that affect when FDA can approve a generic to launch.
- FDA labeling and approval history for generic applications (if any are already pending).
If you share your country (U.S., Canada, UK, etc.), I can tailor the search target to that regulator’s exclusivity/patent system.
What to expect when a generic does become available
Once generic eluxadoline is approved, launch timing can still vary based on:
- Agreement/settlement outcomes between the brand and generic challengers.
- Which patents the generic is permitted to “wait out” before marketing.
Sources
No sources were provided with the prompt, so I can’t cite specific dates for Viberzi’s generic eligibility.